Biocon

This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.

Amgen CEO says Aimovig is “one of most successful launches”

of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.

Roche eyes September FDA verdict for triple NSCLC therapy

Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.
Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars. Already a big player in the emerging biosimilars market, Novartis has struck a deal with India’s Biocon in a bid to ... globally”. The deal with Novartis' subsidiary Sandoz
Mylan gets first biosimilar Herceptin OK from FDA

The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... Mylan said in a statement Ogivri is the
First Herceptin biosimilar cleared in Europe

favour of approval for Biocon and Mylan’s version of the drug in September. ... Biocon and Mylan withdrew the filing for their biosimilar in the EU, after questions were raised about manufacturing quality compliance issues, but said recently these have
Amgen's Mvasi is first FDA-approved cancer biosimilar

Mvasi reaches the market ahead of rival Avastin biosimilars from Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan that are all in late-stage development. Roche insists it has patent protection

More from news
Approximately 9 fully matching, plus 24 partially matching documents found.

Deal Watch May 2016

Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Home based, Senior Medical Writer, Medical Communications: Excellent package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

EU Head of Business Development and Client Service: Exceptional packge and bonus

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Add my company

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”: The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029: Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019: International Women's Day has been celebrated since its inception in 1911. But how far have we come?...